Biofrontera AG B8F
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.35
- Day Range
- €0.32–0.38
- 52-Week Range
- €0.28–1.18
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €22.33 Mil
- Volume/Avg
- 650 / 10,697
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.79
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 92
- Website
- https://www.biofrontera.com
Comparables
Valuation
|
Metric
|
B8F
|
PSG
|
PGMN3
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.76 | 50.31 |
Price/Book Value | 1.61 | 7.34 | 0.54 |
Price/Sales | 0.79 | 2.76 | 0.11 |
Price/Cash Flow | 14.15 | 10.73 | 4.38 |
Price/Earnings
B8F
PSG
PGMN3
Financial Strength
|
Metric
|
B8F
|
PSG
|
PGMN3
|
|---|---|---|---|
Quick Ratio | 1.01 | 2.05 | 0.37 |
Current Ratio | 1.72 | 2.56 | 1.39 |
Interest Coverage | −166.05 | 5.54 | 0.48 |
Quick Ratio
B8F
PSG
PGMN3
Profitability
|
Metric
|
B8F
|
PSG
|
PGMN3
|
|---|---|---|---|
Return on Assets (Normalized) | −30.68% | 11.49% | −0.16% |
Return on Equity (Normalized) | −51.01% | 46.71% | −0.58% |
Return on Invested Capital (Normalized) | −46.13% | 48.84% | 6.02% |
Return on Assets
B8F
PSG
PGMN3
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Tclrqntsnj | Hdm | $76.2 Bil | |
MKKGY
| Merck KGaA ADR | Pjmvygwnp | Sdcrnsj | $70.9 Bil | |
HLN
| Haleon PLC ADR | Brkzvmm | Wldq | $37.8 Bil | |
VTRS
| Viatris Inc | Djbpzptz | Pqw | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Vcsfhhch | Kvtgv | $12.7 Bil | |
CTLT
| Catalent Inc | Zyrkgmqm | Kbfkljm | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Vzntddby | Kldfj | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Nxbfdydhj | Tsxd | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Xhyzgnlb | Qgcwmcz | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Pldbywsny | Slkh | $3.1 Bil |